Wuhan Hiteck Biological Pharma Co Ltd (300683) - Total Liabilities
Based on the latest financial reports, Wuhan Hiteck Biological Pharma Co Ltd (300683) has total liabilities worth CN¥381.30 Million CNY (≈ $55.80 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Wuhan Hiteck Biological Pharma Co Ltd asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Wuhan Hiteck Biological Pharma Co Ltd - Total Liabilities Trend (2013–2025)
This chart illustrates how Wuhan Hiteck Biological Pharma Co Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Wuhan Hiteck Biological Pharma Co Ltd (300683) total assets.
Wuhan Hiteck Biological Pharma Co Ltd Competitors by Total Liabilities
The table below lists competitors of Wuhan Hiteck Biological Pharma Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Jiangsu Fasten Co Ltd
SHE:000890
|
China | CN¥784.10 Million |
|
Anhui Gourgen Traffic Construction Co Ltd
SHG:603815
|
China | CN¥7.49 Billion |
|
Tianjin Jieqiang Power Equipment Co
SHE:300875
|
China | CN¥368.91 Million |
|
Dolphin Drilling AS
OL:DDRIL
|
Norway | Nkr189.80 Million |
|
Chengdu KSW Technologies Co. Ltd. A
SHG:688283
|
China | CN¥167.47 Million |
|
Shanghai Xuerong Bio-Technology Co Ltd
SHE:300511
|
China | CN¥2.43 Billion |
|
Yorhe Fluid Intelligent Control Co Ltd
SHE:002795
|
China | CN¥520.77 Million |
|
VersaBank
NASDAQ:VBNK
|
USA | $5.61 Billion |
Liability Composition Analysis (2013–2025)
This chart breaks down Wuhan Hiteck Biological Pharma Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See 300683 equity financing ratio to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.36 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.18 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.15 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Wuhan Hiteck Biological Pharma Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Wuhan Hiteck Biological Pharma Co Ltd (2013–2025)
The table below shows the annual total liabilities of Wuhan Hiteck Biological Pharma Co Ltd from 2013 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥407.14 Million ≈ $59.58 Million |
-22.46% |
| 2024-12-31 | CN¥525.05 Million ≈ $76.83 Million |
+10.37% |
| 2023-12-31 | CN¥475.73 Million ≈ $69.61 Million |
+28.16% |
| 2022-12-31 | CN¥371.20 Million ≈ $54.32 Million |
+4.72% |
| 2021-12-31 | CN¥354.46 Million ≈ $51.87 Million |
-23.21% |
| 2020-12-31 | CN¥461.62 Million ≈ $67.55 Million |
+12.86% |
| 2019-12-31 | CN¥409.03 Million ≈ $59.85 Million |
-8.24% |
| 2018-12-31 | CN¥445.77 Million ≈ $65.23 Million |
+67.82% |
| 2017-12-31 | CN¥265.62 Million ≈ $38.87 Million |
-20.91% |
| 2016-12-31 | CN¥335.87 Million ≈ $49.15 Million |
+21.81% |
| 2015-12-31 | CN¥275.74 Million ≈ $40.35 Million |
+4.14% |
| 2014-12-31 | CN¥264.78 Million ≈ $38.75 Million |
+42.03% |
| 2013-12-31 | CN¥186.42 Million ≈ $27.28 Million |
-- |
About Wuhan Hiteck Biological Pharma Co Ltd
Wuhan Hiteck Biological Pharma Co.,Ltd, a biopharmaceutical company, engages in the production and sales of bioengineering products and lyophilized powder injections in China and internationally. The company operates through Biopharmaceutical Division; Pharmaceutical Technology Services Division; In Vitro Diagnostic Reagents Division; Production and Sales Division of Active Pharmaceutical Ingredi… Read more